Stocks in play: Fennec Pharmaceuticals Inc.

Today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing the resubmission of its New Drug Application (NDA) for PEDMARK™ (a unique formulation of sodium thiosulfate) for the prevention of ototoxicity induced by cisplatin chemotherapy in patients one month to < 18 years of age with localized, non-metastatic, solid tumors. The Prescription Drug User Fee Act (PDUFA) target action date has been set for November 27, 2021. Fennec Pharmaceuticals Inc. shares T.FRX are trading unchanged at $8.19.

Read:

• Some of the Top Ways to Invest in the Russell 2000 Rebalancing

• This is Why Miners are Investing in Artificial Intelligence

• Here’s What’s Juicing a Potential $1.03 Billion Cold-Pressed Juice Market

• These Are Some of The Top Ways to Trade the Accelerating EV Market

• Cyberattacks in the U.S. Are Expected to Get Worse

• This Superfuel is 9 Times More Effective Than Lithium-Ion Batteries